Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 50

1.

Endothelial Immune Activation by Medin: Potential Role in Cerebrovascular Disease and Reversal by Monosialoganglioside-Containing Nanoliposomes.

Karamanova N, Truran S, Serrano GE, Beach TG, Madine J, Weissig V, Davies HA, Veldhuizen J, Nikkhah M, Hansen M, Zhang W, D'Souza K, Franco DA, Migrino RQ.

J Am Heart Assoc. 2020 Jan 21;9(2):e014810. doi: 10.1161/JAHA.119.014810. Epub 2020 Jan 13.

2.

Drug Development for the Therapy of Mitochondrial Diseases.

Weissig V.

Trends Mol Med. 2020 Jan;26(1):40-57. doi: 10.1016/j.molmed.2019.09.002. Epub 2019 Nov 11. Review.

PMID:
31727544
3.

Conjugation of Triphenylphosphonium Cation to Hydrophobic Moieties to Prepare Mitochondria-Targeting Nanocarriers.

Guzman-Villanueva D, Mendiola MR, Nguyen HX, Yambao F, Yu N, Weissig V.

Methods Mol Biol. 2019;2000:183-189. doi: 10.1007/978-1-4939-9516-5_12.

PMID:
31148015
4.

Cationic amphiphilic bolaamphiphile-based delivery of antisense oligonucleotides provides a potentially microbiome sparing treatment for C. difficile.

Sharma AK, Krzeminski J, Weissig V, Hegarty JP, Stewart DB.

J Antibiot (Tokyo). 2018 Aug;71(8):713-721. doi: 10.1038/s41429-018-0056-9. Epub 2018 Apr 19.

5.

A review of orexin's unprecedented potential as a novel, highly-specific treatment for various localized and metastatic cancers.

Graybill NL, Weissig V.

SAGE Open Med. 2017 Nov 3;5:2050312117735774. doi: 10.1177/2050312117735774. eCollection 2017. Review.

6.

PEGylated-nanoliposomal clusterin for amyloidogenic light chain-induced endothelial dysfunction.

Guzman-Villanueva D, Migrino RQ, Truran S, Karamanova N, Franco DA, Burciu C, Senapati S, Nedelkov D, Hari P, Weissig V.

J Liposome Res. 2018 Jun;28(2):97-105. doi: 10.1080/08982104.2016.1274756. Epub 2017 Feb 10.

7.

Liposomes Came First: The Early History of Liposomology.

Weissig V.

Methods Mol Biol. 2017;1522:1-15. Review.

PMID:
27837526
8.

The Eighth Central European Conference "Chemistry towards Biology": Snapshot.

Perczel A, Atanasov AG, Sklenář V, Nováček J, Papoušková V, Kadeřávek P, Žídek L, Kozłowski H, Wątły J, Hecel A, Kołkowska P, Koča J, Svobodová-Vařeková R, Pravda L, Sehnal D, Horský V, Geidl S, Enriz RD, Matějka P, Jeništová A, Dendisová M, Kokaislová A, Weissig V, Olsen M, Coffey A, Ajuebor J, Keary R, Sanz-Gaitero M, van Raaij MJ, McAuliffe O, Waltenberger B, Mocan A, Šmejkal K, Heiss EH, Diederich M, Musioł R, Košmrlj J, Polański J, Jampílek J.

Molecules. 2016 Oct 17;21(10). pii: E1381.

9.

Mitochondria-Targeted Agents: Mitochondriotropics, Mitochondriotoxics, and Mitocans.

Guzman-Villanueva D, Weissig V.

Handb Exp Pharmacol. 2017;240:423-438. doi: 10.1007/164_2016_37. Review.

PMID:
27590226
10.

Bolaamphiphile-based nanocomplex delivery of phosphorothioate gapmer antisense oligonucleotides as a treatment for Clostridium difficile.

Hegarty JP, Krzeminski J, Sharma AK, Guzman-Villanueva D, Weissig V, Stewart DB Sr.

Int J Nanomedicine. 2016 Aug 1;11:3607-19. doi: 10.2147/IJN.S109600. eCollection 2016.

11.

Monosialoganglioside-Containing Nanoliposomes Restore Endothelial Function Impaired by AL Amyloidosis Light Chain Proteins.

Franco DA, Truran S, Weissig V, Guzman-Villanueva D, Karamanova N, Senapati S, Burciu C, Ramirez-Alvarado M, Blancas-Mejia LM, Lindsay S, Hari P, Migrino RQ.

J Am Heart Assoc. 2016 Jun 13;5(6). pii: e003318. doi: 10.1161/JAHA.116.003318.

12.

Nanoliposomes protect against human arteriole endothelial dysfunction induced by β-amyloid peptide.

Truran S, Weissig V, Madine J, Davies HA, Guzman-Villanueva D, Franco DA, Karamanova N, Burciu C, Serrano G, Beach TG, Migrino RQ.

J Cereb Blood Flow Metab. 2016 Feb;36(2):405-12. doi: 10.1177/0271678X15610134. Epub 2015 Oct 8.

13.

Treatment Strategies that Enhance the Efficacy and Selectivity of Mitochondria-Targeted Anticancer Agents.

Modica-Napolitano JS, Weissig V.

Int J Mol Sci. 2015 Jul 29;16(8):17394-421. doi: 10.3390/ijms160817394. Review.

14.

Nanocarrier-based antioxidant therapy: promise or delusion?

Weissig V, Guzman-Villanueva D.

Expert Opin Drug Deliv. 2015;12(11):1783-90. doi: 10.1517/17425247.2015.1063611. Epub 2015 Jun 29. Review.

PMID:
26119920
15.

Erratum.

Weissig V, Edeas M.

Methods Mol Biol. 2015;1265:E1. doi: 10.1007/978-1-4939-2288-8_33. No abstract available.

PMID:
25835967
16.

Mitochondrial medicine. Preface.

Weissig V, Edeas M.

Methods Mol Biol. 2015;1265:v-xiv. No abstract available.

PMID:
25793241
17.

Mitochondrial medicine. Preface.

Weissig V, Edeas M.

Methods Mol Biol. 2015;1264:v-xiv. No abstract available.

PMID:
25789388
18.

Nanopharmaceuticals (part 2): products in the pipeline.

Weissig V, Guzman-Villanueva D.

Int J Nanomedicine. 2015 Feb 11;10:1245-57. doi: 10.2147/IJN.S65526. eCollection 2015. Review.

19.

DQAsomes as the prototype of mitochondria-targeted pharmaceutical nanocarriers: preparation, characterization, and use.

Weissig V.

Methods Mol Biol. 2015;1265:1-11. doi: 10.1007/978-1-4939-2288-8_1.

PMID:
25634263
20.

Nanopharmaceuticals (part 1): products on the market.

Weissig V, Pettinger TK, Murdock N.

Int J Nanomedicine. 2014 Sep 15;9:4357-73. doi: 10.2147/IJN.S46900. eCollection 2014. Review.

Supplemental Content

Loading ...
Support Center